Multaq Tablet, Film Coated
Product Images NDC 0024-4142
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Multaq (NDC 0024-4142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Multaq 02)
This text appears to be displaying a list of interacting drugs and their corresponding recommendations for use together. Some drugs are contraindicated while others require no dose adjustments. There is mention of antibiotics such as ketoconazole, erythromycin, and rifampin, as well as calcium channel blockers like diltiazem, verapamil, and nifedigine. Statins like simvastatin and atorvastatin are also mentioned. Additionally, there is a warning to avoid concomitant use with grapefruit juice. However, the last line of text is not readable.*
Figure 2 (Multaq 03)
This is a list of medications and their recommended interactions. The medication names include statins, digitalis, beta blockers, calcium channel blockers, antithrombotic agents, Losartan, Metformin, Ethinyl estradiol, Levonorgestrel, Omeprazole, and Theophylline. The information includes recommended dose adjustments for certain drugs when taken together and/or monitoring of certain parameters. There are also some measurements shown for Cmax and AUC.*
Figure 3 (Multaq 04)
Figure 2 (Multaq 05)
Principal Display Panel (60 Tablet Bottle)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.